Compare · HIMS vs OPCH
HIMS vs OPCH
Side-by-side comparison of Hims & Hers Health Inc. (HIMS) and Option Care Health Inc. (OPCH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HIMS and OPCH operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- HIMS is the larger of the two at $6.85B, about 1.5x OPCH ($4.68B).
- HIMS has been more active in the news (10 items in the past 4 weeks vs 4 for OPCH).
- HIMS has more recent analyst coverage (25 ratings vs 17 for OPCH).
- Company
- Hims & Hers Health Inc.
- Option Care Health Inc.
- Price
- -
- -
- Market cap
- $6.85B
- $4.68B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 10
- 4
- Recent ratings
- 25
- 17
Hims & Hers Health Inc.
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available for purchase on its websites directly by customers. It provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, as well as cosmetics and supplement products, primarily focusing on wellness, sexual health, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, collagen protein, biotin, and teas in the wellness category; moisturizer, fragrances, face wash, and anti-wrinkle creams in the skincare category; condoms and lubricants in the sexual health category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. It also offers medical consultation services; and engages in the wholesale of non-prescription product sales to retailers. Hims & Hers Health, Inc. is based in San Francisco, California.
Option Care Health Inc.
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides immunoglobulin infusion therapies for the treatment of immune deficiencies; anti-infective therapies and services; home infusion services to treat heart failures; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders; and immunoglobulin infusion therapies. It also offers infusion therapies for bleeding disorders; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications. In addition, the company offers therapies that women need to survive and thrive through high-risk pregnancies; treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy; and nursing services. The company is headquartered in Bannockburn, Illinois.
Latest HIMS
- SEC Form 4 filed by Hims & Hers Health Inc.
- SEC Form 3 filed by Hims & Hers Health Inc.
- Hims & Hers to Announce Third Quarter 2026 Financial Results on November 9, 2026
- Hers Launches in Australia, Built to Care for the Whole Woman
- SEC Form 8-K filed by Hims & Hers Health Inc.
- Hims & Hers Names Jon Franklin as Chief Accounting Officer
- Chief Financial Officer Okupe Oluyemi sold $59,400 worth of shares (2,000 units at $29.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 234,527 units (SEC Form 4)
- Chief Legal Officer Boughton Soleil sold $100,957 worth of shares (3,461 units at $29.17) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 300,809 units (SEC Form 4)
- Hims & Hers Names Chief Medical Officers in the UK and Australia, Deepening its Investment in Local Clinical Leadership
- Chief Financial Officer Okupe Oluyemi sold $876,846 worth of shares (29,277 units at $29.95) as part of a pre-agreed trading plan and exercised 14,000 shares at a strike of $5.01, decreasing direct ownership by 6% to 236,527 units (SEC Form 4)
Latest OPCH
- SEC Form DEFA14A filed by Option Care Health Inc.
- SEC Form DEFA14A filed by Option Care Health Inc.
- SEC Form 8-K filed by Option Care Health Inc.
- CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health
- Option Care Health to Participate in Upcoming Investor Conferences
- Option Care Health downgraded by Deutsche Bank with a new price target
- SEC Form 10-Q filed by Option Care Health Inc.
- Option Care Health Announces Financial Results For The Second Quarter Ended June 30, 2026
- Option Care Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Option Care Health downgraded by Stephens with a new price target